Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Alnylam Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Alnylam Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 77.4%. For fiscal 2025 it was 81.8%, against 86.4% the year before. The highest annual figure on record is 100.0% in fiscal 2017.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 81.8% | −4.6 |
| FY2024 | Dec 31, 2024 | 86.4% | +1.0 |
| FY2023 | Dec 31, 2023 | 85.3% | −1.2 |
| FY2022 | Dec 31, 2022 | 86.5% | +0.1 |
| FY2021 | Dec 31, 2021 | 86.4% | +1.4 |
| FY2020 | Dec 31, 2020 | 84.9% | −3.6 |
| FY2019 | Dec 31, 2019 | 88.6% | −9.0 |
| FY2018 | Dec 31, 2018 | 97.6% | −2.4 |
| FY2017 | Dec 31, 2017 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 75.2% | −9.0 |
| Q2 FY2026 | Jun 30, 2026 | 76.9% | −4.7 |
| Q1 FY2026 | Mar 31, 2026 | 82.2% | −6.0 |
| Q4 FY2025 | Dec 31, 2025 | 75.6% | −7.1 |
| Q3 FY2025 | Sep 30, 2025 | 84.2% | +0.6 |
| Q2 FY2025 | Jun 30, 2025 | 81.6% | −8.2 |
| Q1 FY2025 | Mar 31, 2025 | 88.2% | −0.8 |
| Q4 FY2024 | Dec 31, 2024 | 82.7% | −0.9 |
| Q3 FY2024 | Sep 30, 2024 | 83.6% | −5.8 |
| Q2 FY2024 | Jun 30, 2024 | 89.8% | +13.4 |
| Q1 FY2024 | Mar 31, 2024 | 89.0% | +1.9 |
| Q4 FY2023 | Dec 31, 2023 | 83.6% | −2.6 |
| Q3 FY2023 | Sep 30, 2023 | 89.4% | +3.2 |
| Q2 FY2023 | Jun 30, 2023 | 76.4% | −8.5 |
| Q1 FY2023 | Mar 31, 2023 | 87.0% | −2.0 |
| Q4 FY2022 | Dec 31, 2022 | 86.2% | −0.8 |
| Q3 FY2022 | Sep 30, 2022 | 86.2% | +1.2 |
| Q2 FY2022 | Jun 30, 2022 | 84.9% | −1.4 |
| Q1 FY2022 | Mar 31, 2022 | 89.0% | +2.0 |
| Q4 FY2021 | Dec 31, 2021 | 87.0% | +0.3 |
| Q3 FY2021 | Sep 30, 2021 | 85.0% | +1.6 |
| Q2 FY2021 | Jun 30, 2021 | 86.3% | +3.9 |
| Q1 FY2021 | Mar 31, 2021 | 87.0% | +0.4 |
| Q4 FY2020 | Dec 31, 2020 | 86.7% | +3.7 |
| Q3 FY2020 | Sep 30, 2020 | 83.5% | −9.1 |
| Q2 FY2020 | Jun 30, 2020 | 82.4% | −7.9 |
| Q1 FY2020 | Mar 31, 2020 | 86.6% | −3.3 |
| Q4 FY2019 | Dec 31, 2019 | 83.0% | −9.1 |
| Q3 FY2019 | Sep 30, 2019 | 92.6% | −0.8 |
| Q2 FY2019 | Jun 30, 2019 | 90.3% | – |
| Q1 FY2019 | Mar 31, 2019 | 89.9% | – |
| Q4 FY2018 | Dec 31, 2018 | 92.1% | – |
| Q3 FY2018 | Sep 30, 2018 | 93.4% | – |
See a number that looks wrong?